Cecile Rose T Vibat
Overview
Explore the profile of Cecile Rose T Vibat including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
222
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gentzler R, Guittar J, Mitra A, Iams W, Driessen T, Schwind R, et al.
Oncol Ther
. 2024 Jul;
12(3):509-524.
PMID: 39037536
Introduction: A dynamic molecular biomarker that can identify early efficacy of immune checkpoint inhibitor (ICI) therapy remains an unmet clinical need. Here we evaluate if a novel circulating tumor DNA...
2.
Reed M, Lyle A, De Loose A, Maddukuri L, Learned K, Beale H, et al.
Cells
. 2021 Dec;
10(12).
PMID: 34943910
Li Fraumeni syndrome (LFS) is a hereditary cancer predisposition syndrome caused by germline mutations in TP53. TP53 is the most common mutated gene in human cancer, occurring in 30-50% of...
3.
Shuford S, Lipinski L, Abad A, Smith A, Rayner M, ODonnell L, et al.
Neurooncol Adv
. 2021 Jun;
3(1):vdab065.
PMID: 34142085
Background: Clinical outcomes in high-grade glioma (HGG) have remained relatively unchanged over the last 3 decades with only modest increases in overall survival. Despite the validation of biomarkers to classify...
4.
Poole J, Wu S, Lu T, Vibat C, Pham A, Samuelsz E, et al.
PLoS One
. 2019 Oct;
14(10):e0223112.
PMID: 31581267
Background: Personalized medicine requires accurate molecular profiling for targeted therapy decisions. Insufficient tissue yield or tumor heterogeneity frequently limits the correct tissue biomarker determination. As a noninvasive complement to traditional...
5.
Lorenzi A, Fregnani J, Dockter J, Fitzgerald K, Strohecker E, Eaton B, et al.
J Low Genit Tract Dis
. 2017 Dec;
22(1):17-20.
PMID: 29271852
Materials And Methods: This is a prospective study, in which 350 patients diagnosed previously with cervical intraepithelial neoplasia (CIN) grade 2 or higher were enrolled. Urine and cervical specimens were...
6.
Cuzick J, Cadman L, Ahmad A, Ho L, Terry G, Kleeman M, et al.
Cancer Epidemiol Biomarkers Prev
. 2017 Feb;
26(7):1053-1059.
PMID: 28223432
Human papillomavirus (HPV) testing from clinician-collected cervical and self-collected cervico-vaginal samples is more sensitive for detecting CIN2/CIN3 than cytology-based screening, stimulating interest in HPV testing from urine. The objective was...
7.
Fujii T, Barzi A, Sartore-Bianchi A, Cassingena A, Siravegna G, Karp D, et al.
Clin Cancer Res
. 2017 Jan;
23(14):3657-3666.
PMID: 28096270
Tumor-derived cell-free DNA (cfDNA) from urine of patients with cancer offers noninvasive biological material for detection of cancer-related molecular abnormalities such as mutations in Exon 2 of A quantitative, mutation-enrichment...
8.
Doshi R, Chen B, Vibat C, Huang N, Lee C, Chang G
Sci Rep
. 2014 Oct;
4:6760.
PMID: 25342225
Nanobodies (Nbs) or single-domain antibodies are among the smallest and most stable binder scaffolds known. In vitro display is a powerful antibody discovery technique used worldwide. We describe the first...
9.
Hyman D, Diamond E, Vibat C, Hassaine L, Poole J, Patel M, et al.
Cancer Discov
. 2014 Oct;
5(1):64-71.
PMID: 25324352
Unlabelled: Patients with Langerhans cell histiocytosis (LCH) and Erdheim-Chester disease (ECD) have a high frequency of BRAF(V600E) mutations and respond to RAF inhibitors. However, detection of mutations in tissue biopsies...
10.
Janku F, Vibat C, Kosco K, Holley V, Cabrilo G, Meric-Bernstam F, et al.
Oncotarget
. 2014 Jul;
5(11):3607-10.
PMID: 25003820
Erdheim-Chester disease (ECD) is a rare histiocytosis with a high prevalence of BRAF V600E mutation (>50% of patients). Patients with BRAF-mutant ECD can respond to BRAF inhibitors. Unfortunately, the lack...